Reported 3 days ago
Eli Lilly and Company (NYSE: LLY) is highlighted as one of billionaire Ken Fisher's top growth stock picks thanks to its strong pipeline of drugs for diabetes and weight loss, including Zepbound and Mounjaro. With a significant equity stake of $4.04 billion from Fisher Asset Management and an impressive revenue growth of 32% in 2024, Eli Lilly is poised for long-term success, especially with plans to invest in manufacturing to meet rising demand.
Source: YAHOO